Learn About Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
University Medical Associates Of The Medical University Of South Carol
Rodney Schlosser is an Otolaryngologist in Charleston, South Carolina. Dr. Schlosser is rated as an Elite provider by MediFind in the treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP). His top areas of expertise are Sinusitis, Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), Cerebrospinal Fluid Leak, Septoplasty, and Endoscopy. Dr. Schlosser is currently accepting new patients.
University Medical Associates Of The Medical University Of South Carol
Zachary Soler is an Otolaryngologist in Charleston, South Carolina. Dr. Soler is rated as an Elite provider by MediFind in the treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP). His top areas of expertise are Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), Sinusitis, Nasal Polyps, Septoplasty, and Endoscopy. Dr. Soler is currently accepting new patients.
Bruce Tan is an Otolaryngologist in Chicago, Illinois. Dr. Tan has been practicing medicine for over 22 years and is rated as an Elite provider by MediFind in the treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP). His top areas of expertise are Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), Nasal Polyps, Sinusitis, Endoscopy, and Nerve Decompression.
Summary: TQC2731 injection is a humanized monoclonal antibody that targets Thymic Stromal Lymphopoietin (TSLP), blocks the TSLP pathway, and inhibits the production of downstream cytokines, thereby exerting anti-inflammatory effects. The purpose of this study is to evaluate the efficacy and safety of TQC2731 injection in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).
Summary: The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in adult participants with chronic rhinosinusitis and nasal polyps treated with intranasal corticosteroids. The study will last about 18 months.